Ziv-aflibercept in Ocular Disease Requiring Anti-VEGF Injection

• Register: ClinicalTrials.gov
• Last refreshed on: 12 December 2020
• Main ID: NCT02486484
• Date of registration: 24/05/2015
• Prospective Registration: No
• Primary sponsor: Rafic Hariri University Hospital
• Public title: Ziv-aflibercept in Ocular Disease Requiring Anti-VEGF Injection Zaltrap
• Scientific title: Phase 2 Ziv-aflibercept in Ocular Disease Short and Long-term Study
• Date of first enrolment: March 2015
• Target sample size: 100
• Recruitment status: Unknown status
• URL: https://clinicaltrials.gov/show/NCT02486484
• Study type: Interventional
• Study design: Allocation: N/A. Intervention model: Single Group Assignment. Primary purpose: Treatment. Masking: None (Open Label).
• Phase: Phase 2

Countries of recruitment

Lebanon

Contacts

• Name: Ahmad M Mansour, MD
• Affiliation: Chair, Department of Ophthalmology, RHUH

• Name: Ahmad Mansour, MD

• Name: Ahmad M Mansour, MD

Key inclusion & exclusion criteria

Inclusion Criteria: All conditions that require anti-VEGF therapy

1. All eye conditions that require anti-VEGF therapy

2. Ability to understand and sign consent form

3. Ability to come for all follow-ups (2 year followup)

4. Acute form of the disease only in naïve cases

Exclusion Criteria:

1. Cardiovascular, cerebrovascular or peripheral vascular event less than 3 months prior
to enrollment

2. Current infection in the eye such as conjunctivitis or keratitis

3. Current upper respiratory tract infection

4. Fever or active body infection

5. Life-threatening disease with short survival

6. late presentation of the disease (chronic end stage disease of the eye)

7. Inability to sign informed consent

8. Inability to come for followups



Age minimum: N/A
Age maximum: N/A
Gender: All

Health Condition(s) or Problem(s) studied

Macular Degeneration

Diabetic Retinopathy

Neovascularization

Choroidal Neovascularization

Cystoid Macular Edema

Retinal Neovascularization

Recurrent Pterygium

Retinal Vein Occlusion

Intervention(s)

Drug: ziv-aflibercept

Primary Outcome(s)

vision before and after ziv-aflibercept [Time Frame: 24 months]

Secondary Outcome(s)

central macular thickness before and after ziv-aflibercept [Time Frame: 24 months]

Secondary ID(s)

RaficHaririUH

Source(s) of Monetary Support

Please refer to primary and secondary sponsors